Penumbra (PEN) vs Stevanato Group S.p.A. (STVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Penumbra (PEN) has outperformed Stevanato Group S.p.A. (STVN) over the past year, gaining 27.0% versus a loss of 19.2%. Over five years, PEN leads with a +18.2% price change compared with -20.1% for STVN. Penumbra is the larger company by market cap ($12.51 billion vs $5.25 billion), about 2.4 times the size.
On valuation, Stevanato Group S.p.A. trades at a lower forward P/E (23.0x vs 51.8x for Penumbra).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PEN | STVN |
|---|---|---|
| Share price | $317.52 | $19.21 |
| Market cap | $12.51B | $5.25B |
| 1-day change | +0.37% | -1.18% |
| YTD return | +1.75% | -3.38% |
| 1-year return | +27.03% | -19.20% |
| 5-year return | +18.15% | -20.07% |
| P/E ratio (TTM) | 78.01 | 33.70 |
| Forward P/E | 51.78 | 23.02 |
| EPS (TTM) | $4.07 | $0.57 |
| Dividend yield | 0.00% | 0.32% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.40B | — |
| Revenue growth (YoY) | +17.50% | — |
| Net income (latest FY) | $177.69M | — |
| Gross margin | 67.14% | — |
| Operating margin | 13.48% | — |
| Net margin | 12.66% | — |
| 52-week high | $362.41 | $27.99 |
| 52-week low | $221.26 | $12.89 |
| Distance from 52-week high | -12.39% | -31.37% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +13.88% | +28.47% |
| Average volume | 344.71K | 370.27K |
| Shares outstanding | 39.39M | 49.83M |
| Employees | 4,700 | 6,010 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Penumbra is about 2.4 times larger than Stevanato Group S.p.A. by market value ($12.51B vs $5.25B).
- PEN has outperformed STVN by 46.2 percentage points over the past year.
- Penumbra trades at a higher earnings multiple (78.0x vs 33.7x trailing P/E).
About Penumbra
PEN stock →Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Health Care · Medical/Dental Instruments · 4,700 employees
About Stevanato Group S.p.A.
STVN stock →Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
Health Care · Medical/Dental Instruments · 6,010 employees
PEN vs STVN FAQ
Which is bigger, Penumbra or Stevanato Group S.p.A.?
Penumbra (PEN) is larger, with a market capitalization of $12.51B compared with $5.25B for Stevanato Group S.p.A. (STVN).
Which stock has performed better over the past year, PEN or STVN?
PEN returned +27.03% over the past 12 months, compared with -19.20% for STVN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PEN or STVN?
STVN has the lower trailing P/E at 33.7, versus 78.0 for PEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Penumbra or Stevanato Group S.p.A.?
Stevanato Group S.p.A. pays a dividend yielding 0.32%, while Penumbra does not currently pay a regular dividend.
Are Penumbra and Stevanato Group S.p.A. in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.